- Home
- Applications
- europe
- cancer cells
Show results for
Refine by
Cancer Cells Product Applications In Europe
17 applications found
Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases. Today, we know that NK cells not only detect and identify malignant cancer ...
ByKiadis Pharma NV based in Amsterdam, NETHERLANDS
Gastric cancer is a disease in which cancer cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas, a cancer that begins in glandular tissue. Gastric cancer is often in an advanced stage when it is diagnosed. At this stage, it can often be treated, but rarely ...
ByAscelia Pharma AB based in Malmö, SWEDEN
IFN-α is a well-known therapeutic that was previously administered systemically for treatment of various cancers but it is currently rarely used because of its systemic toxicity. In the tumor microenvironment, IFN-α exerts its anti-tumor activity both directly by promoting cancer cell apoptosis and inhibiting vascularization and indirectly by restoring anti-tumor immune response. Temferon™ turns TEMs into a “Trojan Horse” to release ...
ByGenenta Science based in Milano, ITALY
One of the that cancer can be a serious disease is its ability to spread to other parts of the body beyond the location of the primary tumour. When cancer cells spread to distant lymph nodes, tissues or organs, it is called metastatic ...
ByAscelia Pharma AB based in Malmö, SWEDEN
BOC Sciences is committed to supplying cost-effective products and services. We provide Peretinoin (Cas No:81485-25-8). More information, please visit the website: http://www.bocsci.com/peretinoin-cas-81485-25-8-item-84-305467.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
The modular fashion with which Affilin® ligands can be fused together makes creating multi-specific binders an easy task. Combined with varying linker lengths, composition, and orientation, plus the optional addition of further accessory modules, our Navigo experts build the designed molecules as previously planned on the drawing ...
ByNavigo Proteins GmbH based in Halle, GERMANY
The development of highly cytotoxic drugs is needed for the success of the treatment in tumor cells. Paradoxically, the high toxicity limits its efficacy and application in vivo, causing damage to non-target organs and severe secondary effects. The use of directed liposomes has allowed the advance of many cancer drugs to preclinical and clinical trials, reducing side effects, and increasing their therapeutic index at the same time. More than 15 cancer liposomed ...
ByNanovex Biotechnologies based in Llanera, SPAIN
BOC Sciences is committed to supplying cost-effective products and services. We provide Halofuginone (Cas No:55837-20-2). More information, please visit the website: http://www.bocsci.com/halofuginone-cas-55837-20-2-item-84-71625.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
Peptides and peptidomimetics constitute excellent tumor-specific targeting moieties and can be coupled to therapeutic and diagnostic radioisotopes via a linker and a ...
By3B Pharmaceuticals GmbH based in Berlin, GERMANY
Downregulating the immune response is necessary for the treatment of autoimmune diseases. In this aspect, the APO2L/TRAIL ligand is a key intermediate in immune cascades and is secreted in exosomes in natural conditions. Its alteration has been associated with rheumatoid arthritis. The administration of synthetic exosomes decorated with APO2L/TRAIL has been shown to be effective in reducing the hyperplasia and overall inflammation in this ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Discover autoantigens in autoimmune diseases, delineate new candidate biomarkers. Autoantibodies are present in the blood of all healthy individuals. However, when directed at high levels against protein targets in specific tissues, autoantibodies can be a major cause of autoimmune diseases. They are also important biomarkers for diagnosis of these conditions. ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM
IMMUNOSCORE® IC is intended for the detection of PD-L1 protein and the concomitant detection of CD8 + cells in Non-Small Cell Lung cancer (NSCLC) ...
ByVeracyte based in Marseille Cedex 9, FRANCE
Deliver the right cells to the patient on time. Maximize Functional Characterization of Your Precious T Cell Samples. The Opto™ Cell Therapy Development workflow accelerates the creation of better therapeutics by performing multiple functional assays across 1,000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link phenotype to gene ...
ByBruker Corporation based in Billerica, MASSACHUSETTS (USA)
To date, the classification of cancers has been based solely on the phenotypic and genotypic characteristics of tumor cells. A new paradigm, scientifically well established and recommended by WHO guidelines, relies on the introduction of the immune response as a new prognostic parameter to predict and refine the clinical outcomes of cancer patients. Maximize patient survival rates with an assessment of the tumor immune response. ...
ByVeracyte based in Marseille Cedex 9, FRANCE
The increase or decrease of a natural immune response to obtain a therapeutic result is the basis of immunotherapy. It holds great promise for the treatment of autoimmune diseases, cancer, and the prevention of transplant ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Laser Force Cytology (LFC) and Radiance label-free approach to cell therapy research and biomanufacturing has significant value in expediting the process, decreasing costs, and ensuring therapy effectiveness and quality. Radiance enhances the highly complex biomanufacturing process for cell therapies by providing new insights to cell therapy research and process development. Current process development assays are fraught with difficult and time-consuming steps requiring highly skilled scientists and bioengineers ...
ByLumaCyte, Inc. based in Charlottesville, VIRGINIA (USA)
Monoclonal antibodies (mAbs) are used to treat patients in a variety of conditions such as infectious disease, cancer, and autoimmunity. Discovery of therapeutic antibodies is a laborious process, that depends on high-throughput screening of antibody candidates to determine antigen specificity. Immune repertoire analysis provides accurate, sensitive, and rapid detection of antibody sequences in panning rounds or exposured animal models, accelerating the discovery of ...
ByEnpicom B.V. based in s-Hertogenbosch, NETHERLANDS